NDAORALTABLETPriority Review
Approved
Sep 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Calcitonin Gene-related Peptide Receptor Antagonists
Pharmacologic Class:
Calcitonin Gene-related Peptide Receptor Antagonist
Clinical Trials (5)
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Started Feb 2025
420 enrolled
Chronic Migraine
Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Started Feb 2025
430 enrolled
Menstrual Migraine (MM)
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
Started Nov 2024
1,000 enrolled
Migraine
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Started Sep 2024
3,000 enrolled
Chronic MigraineEpisodic MigraineMigraine
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Started Mar 2024
1,300 enrolled
Migraine
Loss of Exclusivity
LOE Date
Feb 27, 2043
206 months away
Patent Expiry
Feb 27, 2043
Exclusivity Expiry
Sep 28, 2026